For the first-in-human clinical trial, the dose escalation study design is often utilized. in dose escalation study, subjects are enrolled in cohorts (batches) with increasing doses. whether or not the study goes further to the higher dose depends on the assessment of the previous dose. The assessment is mainly based on the DLT (dose limiting toxicity) - side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Dose escalation study can be with placebo control or without placebo control. For a dose escalation study with placebo control, the placebo control is within each dose cohort, not across the cohorts. A dose escalation study without placebo control is often used in studies for life-threatening diseases such as cancers and AIDS.
The most common dose escalation study design is the rule-based "3 + 3 design". The "3 + 3 design" can be depicted as below:
The "3 + 3 design" is clearly explained in FDA guidance "Clinical Considerations for Therapeutic Cancer Vaccines" as following:
The traditional standard dose escalation schedule in the development of cancer therapeutics uses the so-called “3 + 3 design” to avoid selection of a phase 2 clinical trial dose that causes a treatment-limiting toxicity in more than 17% of subjects, a standard considered acceptable as an outpatient therapeutic for patients with limited options and life-threatening diseases. In a “3 + 3 design,” three patients are initially enrolled into a given dose cohort. If there is no DLT observed in any of these subjects, the trial proceeds to enroll additional subjects into the next higher dose cohort. If one subject develops a DLT at a specific dose, an additional three subjects are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 subjects in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
In summary, the "3 + 3 design" is:
- Rule based design
- Start by allocating lowest dose level to first cohort
- Adaptively escalate/de-escalate based on observed DLTs
- Repeat until MTD obtained or trial is stopped
The "3 + 3 design" is very straight forward, robust, simple and can be very well understood by clinicians and investigators. However, the "3 + 3 design" has its limitations. It is limitations may be summarized as the followings:
- Ignores dosage history other than previous cohort
- Same action under qualitatively different situations (e.g., 0/3 and 1/6 lead to same action)
- Ignores uncertainty (if true DLT rate is p = 0.5, 11% of the time we will see 0 or 1 DLT in 6 patients)
- Cannot re-escalate
- Fixed cohort sizes (either 3 or 6)
- Pre-defined dose levels to be potentially tested
- Low probability of selecting true MTD
- High variability in MTD estimates
- MTD is not a dose with any particular probability of DLT, but in the range from 20% to 25% DLT.
- Can not estimate MTD with target probability of DLT less than 20% or greater than 33%.
- Not all toxicity data of all patients are used to determine the MTD.
- Many patients are likely to be treated at low doses.
The limitations are also cited in FDA's guidance "Clinical Considerations for Therapeutic Cancer Vaccines":
Many cancer vaccine trials have used the “3 + 3 design,” and the results show that, except in very rare situations, an MTD for a cancer vaccine may not be identified. In these trials, the dose-toxicity curve may be so flat that the highest dose that can be administered is limited by manufacturing or anatomic issues rather than toxicity. Therefore, this “3 + 3 design” may not be the most suitable approach to gathering information from early phase trials of cancer vaccines, and alternative trial designs should be considered.
Given the relatively acceptable safety profile of some classes of cancer vaccines, alternative dose-escalation approaches, such as accelerated titration or continuous reassessment, may be considered instead of the standard “3 + 3 design”. When using such designs, the protocol should describe acceptable parameters for the dosing endpoint (supported by data). Irrespective of which dose-escalation approach is chosen, the study protocol should clearly define DLTs, the subject “off-treatment” criteria, and the study stopping rules that will ensure subject safety. When no DLT is expected or achieved, optimization of other outcomes, such as the immune response, can be useful to identify doses for subsequent studies.
Because of these limitations, the alternative phase I dose escalation study designs have been proposed and used in the practice. These methods are:
Insights, advice, suggestions, feedback and comments from experts
As an expert in clinical trial design and dose escalation studies, I would like to provide you with detailed information about the concepts mentioned in the article.
Dose escalation studies are commonly used in first-in-human clinical trials. In these studies, subjects are enrolled in cohorts or batches with increasing doses of the drug or treatment being tested. The decision to proceed to a higher dose depends on the assessment of the previous dose. This assessment is primarily based on DLT (dose limiting toxicity) - which refers to the side effects of the drug or treatment that are serious enough to prevent an increase in dose or level of that treatment.
Dose escalation studies can be conducted with or without placebo control. In a dose escalation study with placebo control, the placebo is administered within each dose cohort, not across different cohorts. On the other hand, a dose escalation study without placebo control is often used in studies for life-threatening diseases such as cancers and AIDS.
The most common dose escalation study design is the rule-based "3 + 3 design." This design is explained in the FDA guidance "Clinical Considerations for Therapeutic Cancer Vaccines." In the "3 + 3 design," three patients are initially enrolled into a given dose cohort. If none of these patients experience a DLT, the trial proceeds to enroll additional patients into the next higher dose cohort. If one patient experiences a DLT at a specific dose, an additional three patients are enrolled into that same dose cohort. If more than one out of six patients in a specific dose cohort experience a DLT, it suggests that the maximum tolerated dose (MTD) has been exceeded, and further dose escalation is not pursued.
The "3 + 3 design" is a rule-based design that starts by allocating the lowest dose level to the first cohort. It adaptively escalates or de-escalates doses based on observed DLTs until the MTD is obtained or the trial is stopped. While the "3 + 3 design" is straightforward and easy to understand, it has its limitations. These limitations include ignoring dosage history other than the previous cohort, taking the same action under qualitatively different situations, ignoring uncertainty, fixed cohort sizes, and pre-defined dose levels to be tested.
Furthermore, the "3 + 3 design" has a low probability of selecting the true MTD and high variability in MTD estimates. It cannot estimate the MTD with a target probability of DLT less than 20% or greater than 33%. Additionally, not all toxicity data of all patients are used to determine the MTD, and many patients are likely to be treated at low doses.
The limitations of the "3 + 3 design" are acknowledged in the FDA's guidance "Clinical Considerations for Therapeutic Cancer Vaccines." The guidance suggests that alternative dose-escalation approaches should be considered for early phase trials of cancer vaccines. Examples of these alternative approaches include CRM (Continual Reassessment Method), Modified CRM, BCRM (Bayesian Logistic Regression Method), and mTPI (Modified Toxicity Probability Interval Design).
These alternative designs take into account the limitations of the "3 + 3 design" and offer more flexibility and accuracy in determining the MTD. The protocol for any dose-escalation approach should clearly define DLTs, subject "off-treatment" criteria, and study stopping rules to ensure subject safety. Additionally, when no DLT is expected or achieved, optimization of other outcomes, such as the immune response, can be useful in identifying doses for subsequent studies.
In summary, dose escalation studies play a crucial role in determining the safe and effective dose of a drug or treatment in first-in-human clinical trials. While the "3 + 3 design" is the most commonly used approach, alternative designs have been proposed to overcome its limitations and improve the accuracy of determining the MTD.
